A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
Public ClinicalTrials.gov record NCT05074433. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants. The secondary objectives of the study are: * To evaluate the safety and tolerability of repeated SC injections of casirivimab+imdevimab in the study population * To characterize concentrations of casirivimab and imdevimab in serum over time * To assess the immunogenicity of casirivimab and imdevimab
Study identification
- NCT ID
- NCT05074433
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 25, 2021 (Actual)
- Primary completion
- May 18, 2022 (Actual)
- Completion
- May 18, 2022 (Actual)
- Last update posted
- Oct 20, 2025
2021 – 2022
United States locations
- U.S. sites
- 66
- U.S. states
- 27
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Alabama Research | Birmingham | Alabama | 35205 | — |
| Baptist Health Center for Clinical Research | Little Rock | Arkansas | 72205 | — |
| Regeneron Study Site | Long Beach | California | 90806 | — |
| Regeneron Study Site | Los Angeles | California | 90033 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| University of California | Sacramento | California | 95817 | — |
| Regeneron Study Site | Stanford | California | 94305 | — |
| James R Berenson MD Inc. | West Hollywood | California | 90069 | — |
| University Of Colorado | Aurora | Colorado | 80045 | — |
| Regeneron Study Site | North Haven | Connecticut | 06473-2195 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Arthritis and Rheumatic Disease Specialties | Aventura | Florida | 33180 | — |
| Innovative Research of West Florida, Inc. | Clearwater | Florida | 33756 | — |
| Midway Immunology and Research Center | Ft. Pierce | Florida | 34982 | — |
| Elixia COVID-19 | Hollywood | Florida | 33024 | — |
| AppleMed Research Group, LLC | Miami | Florida | 33126 | — |
| De La Cruz Research Center, LLC | Miami | Florida | 33184 | — |
| University of South Florida | Tampa | Florida | 33606 | — |
| Florida Medical Clinic, LLC | Zephyrhills | Florida | 33542 | — |
| Regeneron Study Site | Atlanta | Georgia | 30322 | — |
| Regeneron Study Site | Marietta | Georgia | 30060 | — |
| Great Lakes Clinical Trials - Ravenswood | Chicago | Illinois | 60625 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Tulane University | New Orleans | Louisiana | 70112 | — |
| Institute of Human Virology | Baltimore | Maryland | 21201 | — |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| Laboratory of Clinical Immunology and Microbiology, NIAID | Bethesda | Maryland | 20892 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Regeneron Study Site | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Spectrum Health | Grand Rapids | Michigan | 49503 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Jersey Shore University Medical Center | Neptune City | New Jersey | 07753 | — |
| Holy Name | Teaneck | New Jersey | 07666 | — |
| Maimonides Cancer Center | Brooklyn | New York | 11220 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Regeneron Study Site | New York | New York | 10032-3729 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Regeneron Study Site 2 | New York | New York | 10065 | — |
| Regeneron Study Site | Rochester | New York | 14642 | — |
| Regeneron Study Site | Syracuse | New York | 13210 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13215 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Burke Primary Care | Morganton | North Carolina | 28655 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| Regeneron Study Site | Cleveland | Ohio | 44195 | — |
| Miami Valley Hospital | Dayton | Ohio | 45409 | — |
| Altoona Center for Clinical Research | Duncansville | Pennsylvania | 16635 | — |
| Penn Prevention Clinical Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Temple University | Philadelphia | Pennsylvania | 19140 | — |
| Regeneron Study Site | Providence | Rhode Island | 02903 | — |
| West Tennessee Research Institute | Jackson | Tennessee | 38305 | — |
| PharmaTex Research, LLC | Amarillo | Texas | 79109 | — |
| Central Texas Clinical Research | Austin | Texas | 78705 | — |
| Therapeutic Concepts, PA | Houston | Texas | 77004 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Synergy Group Medical,LLC | Houston | Texas | 77087 | — |
| Regeneron Study Site | Richmond | Virginia | 23219 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| Regeneron Study Site | Seattle | Washington | 98109 | — |
| Swedish Medical Center- First Hill | Seattle | Washington | 98122 | — |
| University of Wisconsin - Madison | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05074433, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05074433 live on ClinicalTrials.gov.